Quick answer: All three are once-weekly injections for type 2 diabetes, and they rank in a fairly clear order for blood-sugar and weight results. Mounjaro (tirzepatide) tends to produce the largest A1C drop and the most weight loss because it acts on two hormone receptors. Ozempic (semaglutide) is strong on both and has proven cardiovascular benefit. Trulicity (dulaglutide) is the gentlest and often the most insurance-friendly, but it produces the smallest weight loss of the three.
FormBlends works with semaglutide and tirzepatide for weight management. Here is how the three compare for diabetes and weight.
Which is best: Ozempic, Mounjaro, or Trulicity?
It depends on your goal. For the largest blood-sugar and weight effect, Mounjaro leads. For proven heart protection plus strong results, Ozempic is a top choice. For easy tolerability and often lower cost, Trulicity fits. None is "best" for everyone; the right pick depends on your A1C target, weight goals, heart history, and coverage.
| Factor | Ozempic (semaglutide) | Mounjaro (tirzepatide) | Trulicity (dulaglutide) |
|---|---|---|---|
| Receptor target | GLP-1 | GIP + GLP-1 | GLP-1 |
| A1C reduction | Strong | Largest | Moderate |
| Weight loss | Substantial | Largest | Smallest of the three |
| Dosing | Once weekly | Once weekly | Once weekly |
| Cardiovascular benefit | Established | Reported in CV outcome trial | Established |
| Typical cash price | About $900 to $1,200/mo | About $1,000 to $1,400/mo | About $800 to $1,000/mo |
| Ease of use | Pen, slight prep | Pen | Pen, simplest for many |
How do they compare on blood sugar (A1C)?
Head-to-head trials make this clearer than cross-comparisons.
- In SURPASS-2, the trial that studied tirzepatide against semaglutide 1 mg, tirzepatide lowered A1C by roughly 2.0% to 2.3% across doses versus about 1.9% for semaglutide 1 mg.
- In SUSTAIN-7, the trial that studied semaglutide against dulaglutide, semaglutide lowered A1C more than dulaglutide at matched dose tiers (for example, about 1.8% for semaglutide 1 mg versus about 1.4% for dulaglutide 1.5 mg).
Put together, the typical ranking for A1C lowering is Mounjaro first, Ozempic second, Trulicity third.
How do they compare on weight loss?
Weight loss follows the same order. In SURPASS-2, tirzepatide produced more weight loss than semaglutide 1 mg (roughly 7.6 to 11.2 kg across tirzepatide doses versus about 5.7 kg for semaglutide). In SUSTAIN-7, semaglutide produced more weight loss than dulaglutide (about 6.5 kg for semaglutide 1 mg versus about 3.0 kg for dulaglutide 1.5 mg). Trulicity consistently produces the least weight loss of the three.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →It is worth noting these are diabetes-trial doses. Higher weight-management doses of semaglutide (Wegovy) and tirzepatide (Zepbound) produce larger weight loss than the diabetes versions, but Trulicity has no high-dose weight-management version.
What about heart protection?
All three have meaningful cardiovascular data, with an important nuance:
- Ozempic (semaglutide) showed reduced major adverse cardiovascular events in the SUSTAIN-6 outcomes trial and carries an FDA cardiovascular indication.
- Trulicity (dulaglutide) showed cardiovascular benefit in the REWIND trial and also carries an FDA cardiovascular indication.
- Mounjaro (tirzepatide) reported its dedicated cardiovascular outcomes trial (SURPASS-CVOT) in 2025; for years its CV data lagged the other two, so check the current label with your clinician.
GLP-1 based therapies as a class have reduced cardiovascular events meaningfully in outcome trials, which is a major reason they are favored for people with diabetes and heart risk.
How do side effects compare?
All three are dominated by gastrointestinal effects: nausea, diarrhea, vomiting, and constipation, mostly mild to moderate and worst during dose increases. In general, Trulicity is often described as the gentlest on the stomach, while the stronger drugs (Ozempic and Mounjaro) bring more GI effects alongside their bigger results. All three carry the rodent thyroid-tumor boxed warning and rare risks of pancreatitis, gallbladder problems, and dehydration-related kidney injury.
How do they compare on cost?
Without insurance, all three run roughly $800 to $1,400 a month, with Trulicity usually at the lower end and Mounjaro at the higher end. The bigger driver is coverage. Trulicity has been on the market longest and is often the easiest to get covered for diabetes, while coverage for weight management is more restrictive across the board. Manufacturer savings programs can lower out-of-pocket costs for eligible commercially insured patients.
How do they work?
Trulicity and Ozempic activate the GLP-1 receptor, which curbs appetite, slows stomach emptying, and improves insulin response. Mounjaro adds a second target, the GIP receptor, and that dual action is linked to its larger weight and A1C effects. All three are injected once weekly.
Which should you choose?
For diabetes with weight loss as a strong goal, Mounjaro offers the biggest effect. For diabetes plus established heart protection and strong results, Ozempic is a solid choice. For someone prioritizing tolerability and coverage who needs moderate help, Trulicity fits. If weight loss is your main goal, the weight-management versions (Wegovy, Zepbound) are worth discussing too. Compare your options with a clinician using the FormBlends provider comparison tool or the semaglutide overview.
Frequently asked questions
Is Trulicity better than Mounjaro?
For blood-sugar and weight results, Mounjaro is generally stronger. Trulicity is often gentler and easier to get covered, so "better" depends on your goals.
Mounjaro vs Trulicity, which lowers A1C more?
Mounjaro lowers A1C more on average. Trulicity is effective but produces a smaller reduction.
Trulicity vs Mounjaro cost, which is cheaper?
Trulicity usually has a lower cash price and is often easier to get covered, while Mounjaro tends to cost more.
Ozempic vs Mounjaro vs Trulicity for weight loss?
Mounjaro produces the most weight loss, Ozempic next, and Trulicity the least, based on the trials that studied them.
Do all three protect the heart?
Ozempic and Trulicity have established cardiovascular benefit. Mounjaro reported its cardiovascular outcomes trial in 2025; confirm the current label with your clinician.
Which has the fewest side effects?
Trulicity is often described as the gentlest on the stomach. All three share the same types of GI side effects, worst during dose increases.
Can I switch between them?
Yes, under medical supervision, with a fresh dose-escalation plan. People sometimes switch for tolerability, cost, or coverage reasons.
Are these for diabetes or weight loss?
All three are approved for type 2 diabetes. For weight management, the related products are Wegovy (semaglutide) and Zepbound (tirzepatide); Trulicity has no weight-management version.
Related guides
- Ozempic vs Trulicity: Semaglutide vs Dulaglutide for Diabetes
- Zepbound vs Trulicity: Which GLP-1 Medication Delivers Better Results for Weight Loss and Diabetes Control?
- Trulicity vs Wegovy: Which GLP-1 Medication Works Better for Weight Loss and Diabetes?
- Victoza vs Trulicity: Which GLP-1 Medication Works Better for Diabetes and Weight Loss?
- Ozempic vs Mounjaro vs Wegovy: The Big 3 Weight Loss Injections Compared (2025)
- Research Peptides vs Prescribed Therapy: Safety & Legality Compared
Sources
- Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021. https://pubmed.ncbi.nlm.nih.gov/33812497/
- Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN-7). Lancet Diabetes Endocrinol, 2018. https://pubmed.ncbi.nlm.nih.gov/29397376/
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016. https://pubmed.ncbi.nlm.nih.gov/27633186/
- Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet, 2019. https://pubmed.ncbi.nlm.nih.gov/31189511/
- FDA Prescribing Information, Mounjaro (tirzepatide). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →